Blindsight, the experimental vision-restoring implant by Elon Musk’s brain-chip startup, Neuralink, has received the U.S. Food and Drug Administration’s (FDA) "breakthrough device" designation, according to the company.

Elon Musk's brain-chip startup Neuralink said on Tuesday its experimental implant aimed at restoring vision received the U.S. Food and Drug Administration's "breakthrough device" designation.

The regulatory approval is just the first phase of a long project, but Neuralink owner Elon Musk is already touting his brain implant tech as a world-changing solution for people with vision loss.

Elon Musk's Neuralink has achieved a milestone with the FDA's "breakthrough device" designation for its vision implant, Blindsight.

T-Mobile is making a bold move into AI in 2024, partnering with OpenAI to revolutionize how it handles customer support.